Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective Study

In our retrospective study, patients with IVIG-resistant Kawasaki disease whose first re-treatment was with infliximab, compared with IVIG, had faster resolution of fever and fewer days of hospitalization. Coronary artery outcomes and adverse events were similar; the power of the study was limited.